Drug Profile

Nesolicaftor - TuHURA Biosciences

Alternative Names: PTI-428

Latest Information Update: 03 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Proteostasis Therapeutics
Developer TuHURA Biosciences
Class Antifibrotics; Small molecules
Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Cystic fibrosis
New Molecular Entity Yes
Available For Licensing Yes - Cystic fibrosis

Highest Development Phases

Phase II Cystic fibrosis

Most Recent Events

30 Jun 2025 Kineta has been acquired and merged into TuHURA Biosciences
31 Dec 2023 Nesolicaftor licensed to Fair Therapeutics
19 Dec 2022 Yumanity Therapeutics has merged with Kineta to form Kineta

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com